We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Resverlogix' RVX-208 is the First BET Bromodomain Inhibitor in Clinical Trials

News   Jul 24, 2012

 
Resverlogix' RVX-208 is the First BET Bromodomain Inhibitor in Clinical Trials
 
 
 

RELATED ARTICLES

Potential Therapeutic Target for Alzheimer's

News

A previously unknown gene and associated protein which could potentially be suppressed to slow the advance of Alzheimer’s have been discovered, presenting a potential therapeutic target to combat the disease.

READ MORE

Cell Biology: All in a Flash!

News

Researchers have developed a method for eliminating essential proteins from cells with a flash of light, making it possible to study the function of essential proteins.

READ MORE

New Glaucoma Test To Help Prevent Blindness

News

After identifying 107 genes that increase a person’s risk of developing the eye disease glaucoma, researchers have now developed a genetic test to detect those at risk of going blind from it.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE